Sumitomo Mitsui Trust Group Inc. Has $1.86 Million Stock Holdings in Medpace Holdings, Inc. $MEDP

Sumitomo Mitsui Trust Group Inc. lowered its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 21.4% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,872 shares of the company’s stock after selling 1,055 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Medpace were worth $1,859,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in MEDP. Geneos Wealth Management Inc. grew its position in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after acquiring an additional 37 shares during the last quarter. Steigerwald Gordon & Koch Inc. acquired a new stake in shares of Medpace in the fourth quarter valued at $30,000. Elyxium Wealth LLC bought a new position in shares of Medpace in the fourth quarter valued at about $30,000. Quarry LP bought a new position in shares of Medpace in the third quarter valued at about $35,000. Finally, Bayban acquired a new position in Medpace during the 4th quarter worth about $44,000. 77.98% of the stock is owned by institutional investors.

Medpace Price Performance

MEDP opened at $529.23 on Thursday. The company has a market cap of $15.11 billion, a price-to-earnings ratio of 33.26, a price-to-earnings-growth ratio of 2.72 and a beta of 1.15. The firm has a 50 day simple moving average of $473.64 and a 200 day simple moving average of $494.66. Medpace Holdings, Inc. has a fifty-two week low of $306.70 and a fifty-two week high of $628.92.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The firm had revenue of $706.60 million for the quarter, compared to analysts’ expectations of $697.82 million. During the same period last year, the firm earned $3.67 earnings per share. The business’s revenue for the quarter was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, analysts expect that Medpace Holdings, Inc. will post 17.04 EPS for the current year.

Insider Activity

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the sale, the general counsel directly owned 20,343 shares of the company’s stock, valued at $9,154,350. The trade was a 44.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 20.50% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on MEDP shares. Mizuho increased their price objective on shares of Medpace from $495.00 to $586.00 and gave the stock an “outperform” rating in a report on Monday. Wall Street Zen downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Royal Bank Of Canada reduced their target price on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. BMO Capital Markets decreased their price target on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a research note on Friday, April 24th. Finally, Barclays dropped their price objective on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a research report on Friday, April 24th. Two research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $469.50.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.